


Patent claims

1. A compound of formula



wherein

R_1 is (C₁₋₄)alkyl,

R_2 is unsubstituted (C₁₋₄)alkyl or (C₁₋₄)alkyl substituted by unsubstituted or substituted
- (C₆₋₁₈)aryl or

- (C₆₋₁₈)aryl annelated with heterocyclyl having 5 or 6 ring members and 1 to 4
heteroatoms selected from N, O, S,

R_3 is (C₆₋₁₈)aryl one or morefold substituted by

- halogen,

- halo(C₁₋₆)alkyl,

- halo(C₁₋₆)alkoxy,

- cyano,

- phenyl,

- heterocyclyl having 5 to 6 ring members and 1 to 4 heteroatoms selected from N, O,
S.

2. A compound of claim 1 wherein

R_1 is methyl,

R_2 is methyl or

methyl substituted by

- quinoliny,

- benzo[1,3]dioxolyl,

- phenyl

- phenyl one or morefold substituted by halogen, halo(C₁₋₄)alkyl, (C₁₋₄)alkoxy, cyano,
amino, dimethylamino, carboxy(C₁₋₂)alkylcarbonylamino,
amino(C₁₋₂)alkylcarbonylamino, (C₂₋₄)alkylenecarbonylamino,


- 37 -

heterocyclylcarbonyl(C₁₋₂)alkylcarbonylamino, wherein heterocyclyl has 6 ring members and 2 heteroatoms selected from N, O,

- R₃ is phenyl one or morefold, e.g. 1- to 3-fold, substituted by

- halogen,
- halo(C₁₋₂)alkyl,
- halo(C₁₋₂)alkoxy,
- cyano,
- phenyl,
- heterocyclyl, including aromatic, having 6 ring members and 2 nitrogen heteroatoms.

3. A compound of claim 1 or 2 of formula



4. A compound of any one of claims 1 to 3 in the form of a salt.
5. A compound of formula I according to any one of claim 1 to 4 for use as a pharmaceutical.
6. The use of a compound of any one of claims 1 to 4 for the manufacture of a medicament for the treatment of disorders or diseases mediated by LFA-1/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions.
7. A pharmaceutical composition comprising a compound of formula I according to any one of claim 1 to 4 in association with at least one pharmaceutical excipient.
8. A pharmaceutical composition according to claim 7, further comprising another pharmaceutically active agent.

- 38 -

9. A method for treatment of disorders or diseases mediated by LFA-1/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I according to any one of claims 1 to 4.
10. A method according to claim 9, wherein a compound of any one of claims 1 to 4 is administered in combination with another pharmaceutically active agent, either simultaneously or in sequence.

IL/12-Dec-2003